Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM
During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, María‑Victoria Mateos chaired a recorded discussion that also featured Nina Shah, Paul Richardson, Morie Gertz, and Heinz Ludwig. The topic of this discussion was “Integrating B-cell maturation antigen (BCMA)-directed agents in the treatment landscape for relapsed/refractory multiple myeloma”, which was identified as an unmet need within multiple myeloma treatment.
Mateos begins the discussion by posing the question of how to integrate chimeric antigen receptor (CAR) T-cell and other BCMA-directed products into…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.